ME-344

ME-344 is a synthetic small molecule and an investigational antineoplastic agent that acts as a selective inhibitor of mitochondrial oxidative phosphorylation (OXPHOS), specifically targeting complex I. By inhibiting OXPHOS in tumor cells—especially when glycolysis is suppressed by antiangiogenic agents like bevacizumab—ME-344 disrupts ATP production and induces energy starvation. This leads to cancer cell death via both caspase-dependent and caspase-independent mechanisms including destructive autophagy. Preclinical studies have shown tumor-selective activity; clinical trials have evaluated its use in solid tumors such as ovarian cancer, small cell lung cancer, breast cancer (HER2-negative), and metastatic colorectal cancer. The drug was originally developed by Novogen and further developed by MEI Pharma[1][5][6][7].

Brand names

ME-344ME344ME 344

Other names

4,4'-(7-Hydroxy-8-methylchroman-3,4-diyl)diphenol(3R,4S)-3,4-bis(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H-chromen-7-olUNII-843G0TDV51UNII843G0TDV51UNII 843G0TDV51